 |
Renvela, right from the start
Renvela® is an effective first-line monotherapy for controlling serum phosphorus in patients with Chronic Kidney Disease (CKD) — on dialysis without calcium or metal1 accumulation.
References: 1. Renvela [package insert]. Cambridge, MA: Genzyme Corp; 2007.
|
|
|
|
|
|
|
Important Treatment Considerations
Renvela® (sevelamer carbonate) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis
- Renvela is contraindicated in patients with bowel obstruction
- Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation, or major GI tract surgery
- Uncommon cases of bowel obstruction and perforation have been reported
- Serum bicarbonate and chloride levels should be monitored
- Vitamins D, E, K (coagulation parameters), and folic acid levels should be monitored
- The most frequently occurring adverse reactions in a short-term study with sevelamer carbonate tablets were nausea and vomiting
- In a short-term study of sevelamer carbonate powder dosed three times daily, adverse events were similar to those reported for sevelamer carbonate tablets
- In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included: vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation
- Cases of fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation have been reported
- Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renvela
- Patients should be informed to take Renvela with meals and to adhere to their prescribed diets
Please see accompanying full Prescribing Information.
Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis
- Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction
- Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery
- Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation
- Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction
- Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel
- Patients should be informed to take Renagel with meals and to adhere to their prescribed diets
Please see accompanying full Prescribing Information.
|
|
|
|
|
|
 |
Genzyme Corporate
